Display options
Cite
Jaffary F, Nilforoushzadeh MA, Siadat A, et al. A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions. Dermatol Res Pract. 2016;2016:6462804doi: 10.1155/2016/6462804.
Jaffary, F., Nilforoushzadeh, M. A., Siadat, A., Haftbaradaran, E., Ansari, N., & Ahmadi, E. (2016). A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions. Dermatology research and practice, 20166462804. https://doi.org/10.1155/2016/6462804
Jaffary, Fariba, et al. "A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions." Dermatology research and practice vol. 2016 (2016): 6462804. doi: https://doi.org/10.1155/2016/6462804
Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N, Ahmadi E. A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions. Dermatol Res Pract. 2016;2016:6462804. doi: 10.1155/2016/6462804. Epub 2016 Apr 11. PMID: 27148363; PMCID: PMC4842369.
Copy Download .nbib Format: NLM
Share it on

Dermatol Res Pract. 2016;2016:6462804. doi: 10.1155/2016/6462804. Epub 2016 Apr 11.

A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions.

Dermatology research and practice

Fariba Jaffary, Mohammad Ali Nilforoushzadeh, Amirhossein Siadat, Elaheh Haftbaradaran, Nazli Ansari, Elham Ahmadi

Affiliations

  1. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan 8187698191, Iran; Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran 1937957514, Iran.
  2. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran 1937957514, Iran.
  3. Department of Dermatology, Isfahan University of Medical Sciences, Isfahan 8174675731, Iran.
  4. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan 8187698191, Iran.

PMID: 27148363 PMCID: PMC4842369 DOI: 10.1155/2016/6462804

Abstract

Background. Cutaneous leishmaniasis is an endemic disease in Iran. Pentavalent antimonial drugs have been the first line of therapy in cutaneous leishmaniasis for many years. However, the cure rate of these agents is still not favorable. This study was carried out to compare the efficacies of intralesional glucantime with topical trichloroacetic acid 50% (TCA 50%) + glucantime and fractional carbon dioxide laser + glucantime in the treatment of cutaneous leishmaniasis. Methods. A total of 90 patients were randomly divided into three groups of 30 to be treated with intralesional injection of glucantime, a combination of topical TCA 50% and glucantime, or a combination of fractional laser and glucantime. The overall clinical improvement and changes in sizes of lesions and scars were assessed and compared among three groups. Results. The mean duration of treatment was 6.1 ± 2.1 weeks in all patients (range: 2-12 weeks) and 6.8 ± 1.7, 5.2 ± 1.0, and 6.3 ± 3.0 weeks in glucantime, topical TCA plus glucantime, and fractional laser plus glucantime groups, respectively (P = 0.011). Complete improvement was observed in 10 (38.5%), 27 (90%), and 20 (87%) patients of glucantime, glucantime + TCA, and glucantime + laser groups, respectively (P < 0.001). Conclusion. Compared to glucantime alone, the combination of intralesional glucantime and TCA 50% or fractional CO2 laser had significantly higher and faster cure rate in patients with cutaneous leishmaniasis.

References

  1. Indian J Dermatol. 2011 Mar;56(2):171-3 - PubMed
  2. Lancet Infect Dis. 2007 Sep;7(9):581-96 - PubMed
  3. Lasers Med Sci. 2014 Mar;29(2):855-7 - PubMed
  4. Postgrad Med J. 2007 Feb;83(976):649-57 - PubMed
  5. Semin Cutan Med Surg. 2012 Jun;31(2):105-9 - PubMed
  6. BMC Complement Altern Med. 2007 Apr 27;7:13 - PubMed
  7. Clin Dermatol. 1996 Sep-Oct;14(5):425-31 - PubMed
  8. Bull World Health Organ. 1991;69(1):103-6 - PubMed
  9. J Cutan Med Surg. 2010 Nov-Dec;14(6):303-6 - PubMed
  10. J Vector Borne Dis. 2013 Mar;50(1):30-7 - PubMed
  11. PLoS One. 2012;7(5):e35671 - PubMed
  12. PLoS Negl Trop Dis. 2008;2(10):e259 - PubMed
  13. J Investig Dermatol Symp Proc. 2001 Dec;6(3):175-82 - PubMed
  14. J Dermatolog Treat. 2012 Apr;23(2):136-9 - PubMed
  15. J Dermatol. 2012 Apr;39(4):321-5 - PubMed
  16. Adv Biomed Res. 2014 Dec 31;3:259 - PubMed
  17. PLoS Med. 2006 May;3(5):e162 - PubMed
  18. Clin Infect Dis. 2001 Dec 1;33(11):1847-51 - PubMed
  19. J Eur Acad Dermatol Venereol. 2011 May;25(5):587-91 - PubMed
  20. Cochrane Database Syst Rev. 2008 Oct 08;(4):CD005067 - PubMed
  21. Int J Dermatol. 2004 Oct;43(10):736-8 - PubMed
  22. Exp Dermatol. 2012 Jul;21 Suppl 1:8-10 - PubMed
  23. J Antimicrob Chemother. 2013 Dec;68(12):2834-8 - PubMed

Publication Types